Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial

Study schema for double-blind period. PASI, Psoriasis Area and Severity Index; PASI 50, 50% improvement in PASI score; W, week.

Improvements in Children's Dermatology Life Quality Index (CDLQI) total scores over time. Data represent median (solid line) and mean (broken line) percentage improvements in total CDLQI score in patients receiving etanercept (dark black line) versus placebo (light gray line) during double-blind portion of study. Error bars represent SEM. Placement of data points has been skewed to enhance visibility. ^aMedian total CDLQI scores at baseline were 7 for etanercept group and 10 for placebo group. ^bMean total CDLQI scores at baseline were 9 for etanercept group and 10 for placebo group. ^cDuring double-blind period, patients who entered the escape arm at or after week 4 were imputed as treatment failures through week 12. ^dSlope was interpolated between weeks 4 and 12 as measurements were not taken at weeks 6, 8, and 10.

Children's Dermatology Life Quality Index (CDLQI) total score percentage improvements for etanercept group by 75% improvement in Psoriasis Area and Severity Index score (PASI 75) response. Data represent median (solid line) and mean (broken line) percentage improvements in total CDLQI score over time for patients who did (dark black line) and did not (light gray line) achieve PASI 75 during double-blind portion of study. Error bars represent SEM. Placement of data points has been skewed to enhance visibility. ^aMedian total CDLQI scores at baseline were 9 for PASI 75 achievers and 6 for PASI 75 nonachievers. ^bMean total CDLQI scores at baseline were 10 for PASI 75 achievers and 8 for PASI 75 nonachievers. ^cSlope was interpolated between weeks 4 and 12 as measurements were not taken at weeks 6, 8, and 10.